



SenzaGen receives SEK 1m follow-on order for GARD®skin Dose-Response from one of the world's largest cosmetics companies

Lund, December 1, 2021

SenzaGen secured another project to test ingredients in cosmetics products from one of the largest cosmetics companies in the world. The new order is valued at around SEK 1 million and is for the Company's unique in vitro test, GARD®skin Dose-Response. The testing is performed at SenzaGen's GLP-certified laboratory in Lund, Sweden.

In July, SenzaGen received an evaluation order for GARD®skin Dose-Response from the customer, a world leader in beauty and cosmetics. The company used this test to study the dose at which a substance in a cosmetics product does not cause an allergic reaction, and it has now chosen to evaluate more substances.

"We are very pleased that the customer is satisfied with the initial evaluation phase of GARD®skin Dose-Response and is proceeding to test more ingredients. This is a crucial project with a major customer, in particular, because the test meets needs for which businesses and researchers in the cosmetics industry have sought a solution for a long time. We look forward to continuing to supply the customer with data that can help them ensure their products do not cause allergic reactions. In the second half of the year, we have seen continued strong interest from multiple companies in diverse industries, especially in our recently launched GARD®skin Dose-Response test. Existing customers are placing follow-on orders and our customer base is growing with new customers, which is very satisfying" says Peter Nählstedt, CEO of SenzaGen.

GARD®skin Dose-Response is a test based on genomic data and machine learning that provides information on the dose at which a substance causes allergy. This makes it possible for research and development to be conducted without the use of animal testing. The test enables companies in the cosmetics, pharmaceuticals and chemicals industries to identify the highest possible quantity of a chemical that they can include in their products ("the Dose of Departure"). This serves as crucial information for prioritization and decision-making in research and development. The new test is a new application domain of GARD®skin, and it is one of the first of its kind on the market.

Contacts

Peter Nählstedt, CEO, SenzaGen AB

Email: peter.nahlstedt@senzagen.com | Tel: +46 46 275 6201

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708-20 29 44



About us

SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® test platform, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. The Company's state-of-the-art GARD® test platform combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. Its high informational content and a holistic view of immunological responses contribute to high predictive accuracy and human relevance. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company's Certified Adviser.

Attachments

[SenzaGen receives SEK 1m follow-on order for GARD®skin Dose-Response from one of the world's largest cosmetics companies](#)